ABSTRACT
Clinical trials in CFS are difficult to perform and evaluate because of the heterogeneity of patient populations and the complexity of illness origin. Therefore, it has been suggested that data should be analyzed by comparing different groups of patients (e.g., gradual vs. sudden onset, symptom severity, etc.).
